MRNA- and Adenovirus-Based Vaccines against SARS-CoV-2 in HIV-Positive People.

ABSTRACT: About two years have passed since the identification of SARS-CoV-2 in China. The rapid spread of this virus all over the world and its high transmissibility and pathogenicity in humans have resulted in a global pandemic. The negative impact of COVID-19 on health, society and the economy at the global level has pushed researchers and pharmaceutical companies to develop effective vaccines to fight SARS-CoV-2. Thanks to this collaborative effort, the first COVID-19 vaccine was developed in less than a year. Since then, several COVID-19 vaccines have been validated for use by the World Health Organization. Among these, mRNA- (BNT162b2 and mRNA1273) and adenovirus-based (ChAdOx1) vaccines were developed through the use of novel technologies. While all three of these vaccines have shown effectiv

SUBMITTER: Garbuglia AR 

PROVIDER: S-EPMC9031858 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature